Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Stockholders' Equity

v3.25.2
Consolidated Statements of Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Equity, beginning balance at Jun. 30, 2023 $ 1 $ 304,320 $ (288,940) $ 15,381
Equity, beginning balance (shares) at Jun. 30, 2023 1,015      
Common stock issued $ 8 25,120   25,128
Common stock issued (shares) 7,568      
Payments for fractional shares resulting from reverse stock split   (7)   (7)
Payments for fractional shares resulting from reverse stock split (shares) (1)      
Vesting of RSUs (shares) 42      
Share-based compensation   2,038   2,038
Warrant issued to satisfy term note payable   3,691   3,691
Net loss     (24,907) (24,907)
Equity, ending balance at Jun. 30, 2024 $ 9 335,162 (313,847) 21,324
Equity, ending balance (shares) at Jun. 30, 2024 8,624      
Common stock issued for warrants exercised $ 6 5,871   5,877
Common stock issued for warrants exercised (shares) 5,627      
Common stock issued $ 4 3,642   3,646
Common stock issued (shares) 4,744      
Vesting of RSUs (shares) 35      
Exercise of stock options   130   130
Exercise of stock options (shares) 73      
AstrialBio Exclusive License Agreement shares issued   750   750
AstrialBio Exclusive License Agreement shares issued (shares) 246      
Share-based compensation   1,530   1,530
Net loss     (18,377) (18,377)
Equity, ending balance at Jun. 30, 2025 $ 19 $ 347,085 $ (332,224) $ 14,880
Equity, ending balance (shares) at Jun. 30, 2025 19,349